CF Foundation | National Annual Meeting 2025

During the fifth National Annual Meeting, the Foundation's President and CEO, Michael Boyle, MD, along with our Executive Vice President and Chief Operating and Financial Officer, Irena Barisic, shared what’s ahead for 2025. Originally recorded January 22, 2025. 0:00 | National Annual Meeting 2025 01:34 | President and CEO, Michael Boyle, MD welcomes the audience to the National Annual Meeting 02:15 | What announcements did the FDA make that were wins for the CF community? 03:49 | What is the difference between Trikafta and Alyftrek? 05:27 | What are the CF Foundation’s scientific and care priorities for 2025? 10:40 | Executive Vice President and Chief Operating and Financial Officer, Irena Barisic, discusses key strategy projects for 2025 12:34 | Assessing the results of the long-term strategic plan survey 16:10 | What is the goal of the CF Foundation’s financial strategy? 19:40 | What science in genetic therapies is Executive Vice President and Chief Scientific Officer, Steven Rowe, MD excited about? 26:54 | What are the Foundation’s top advocacy priorities for 2025? 35:14 | What questions should people with CF be asking providers in clinic about Alyftrek? 38:15 | Why is it important to monitor liver function on Alyftrek? 40:04 | What is the Foundation doing to learn more about the potential mental health side effects of modulators? 43:15 | What is the Foundation doing to help those with cystic fibrosis-related diabetes? 45:45 | What is the Foundation doing to help with GI issues in people with CF? 49:30 | What is the Foundation doing to help those with CF who are interested in having families? 53:43 | Can people with lung transplants benefit from modulators? 55:38 | Is insurance covering Alyftrek? 58:23 | What mutations aren’t benefitting from modulators? 1:02:10 | Why is community so important to the Foundation’s mission?